The cancer changes the growth and development of leukocytes (white blood cells ... cancer. B symptoms of lymphoma include fevers, unintentional weight loss, and drenching night sweats. Lymphoma can be ...

The Central Drugs Standard Control Organisation (CDSCO) has approved Chimeric Antigen Receptor or CAR T-cell, named Qartemi by Immuneel Therapeutics, for adult B-cell Non-Hodgkin Lymphoma (B-NHL ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a ...

NEW DELHI: India’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a kind of blood cancer that affects the lymphatic system, has been launched in the country ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

the company’s first product for adult B-cell Non-Hodgkin Lymphoma (B-NHL). Benchmarked to international standards, this personalised therapy is for adults with relapsed B-NHL, said Immuneel ...

country’s first global CAR T-cell therapy for adult B-cell non-Hodgkin lymphoma (B-NHL). A personalized therapy for adult patients with relapsed or refractory B-NHL, the company which is India’s ...

a CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL). According to the company’s statement, it is personalized therapy for adult patients with relapsed or refractory B-NHL.

Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat.